BCI-1283

BCI-1283 is a small molecule, selective agonist of the melanocortin-4 receptor (MC4R) originally developed by BrainCells Inc. and later licensed by Biozeus (in partnership with Biocane) for the treatment of obesity and metabolic disorders. The melanocortin system, specifically the MC4R pathway located in the hypothalamus, is a central regulator of energy homeostasis, appetite, and body weight. Activation of MC4R by BCI-1283 is intended to reduce food intake and increase energy expenditure. While the compound was initially explored by BrainCells Inc. for its neurogenic properties in the context of central nervous system disorders like depression, its development by Biozeus has focused on its potential as an anti-obesity agent. The drug is designed for oral administration and has demonstrated efficacy in preclinical models of weight management.

Other names

BCI 1283BCI1283BCI-1283